What did @crpeptideos actually say?
Honestly, this is a difficult video to fact-check because the transcript is nearly incoherent. The creator claims to demonstrate "precise measurement in the syringe after reconstitution of GHK-Cu" and says that "correct fractionation makes all the difference in results." But the spoken content captured doesn't actually explain a fractionation protocol, a dosing rationale, or any mechanism of action. What we have is a caption making specific procedural claims that the video content does not appear to support with any real explanation.
The caption does include one reasonable caveat: "always use sterile materials and follow an adequate protocol." That part is not wrong. But a caption disclaimer does not substitute for accurate, legible instruction, especially when 6,500 people are watching someone handle a reconstituted peptide solution and potentially taking notes.
Does the science back this up?
The underlying compound, GHK-Cu (copper tripeptide-1), does have a legitimate research base, which makes content like this more frustrating than outright fake. The problem is what gets lost in translation between the science and the syringe tutorial.
GHK-Cu is a naturally occurring copper complex first isolated from human plasma. Research from Pickart and Margolina (2018, Cosmetics) describes its role in wound healing, anti-inflammatory signaling, and collagen synthesis stimulation. A 2012 study by Pickart published in the Journal of Biomaterials Science found GHK-Cu promoted nerve regeneration in animal models. Importantly, most of this research is in vitro or animal-based. Human clinical trial data on injected GHK-Cu is sparse, and no fractionation schedule has been validated in a peer-reviewed human trial.
The claim that fractionation, meaning splitting a vial dose into multiple smaller injections over time, improves results is plausible in theory. Peptide half-lives are short. GHK-Cu's plasma half-life is not well characterized in humans. But "plausible in theory" is not the same as "demonstrated in a controlled study."
What did they get wrong (or right)?
The caption gets the sterility message right. Reconstituted peptides dissolved in bacteriostatic water are not sterile in a pharmaceutical sense, and contamination risk is real. Reminding viewers to use sterile materials is the minimum responsible thing to say, and credit is due there.
What is missing or potentially wrong is more significant. There is no explanation of why a specific fractionation approach was chosen, no citation of any protocol, and no acknowledgment that GHK-Cu sold outside licensed pharmaceutical channels is not FDA-approved for injection. The framing that fractionation produces better results implies a dose-response relationship that has not been established in humans for subcutaneous or intramuscular GHK-Cu administration.
Showing syringe measurement technique without explaining concentration, reconstitution volume, or injection site is genuinely incomplete, and in a regulated context, that gap matters. A viewer who miscalculates concentration could inject a dose ten times higher than intended.
What should you actually know?
GHK-Cu is one of the more studied peptides in the cosmetic and dermatology space, but its injectable use is a different category entirely from topical application. Most of the published human data involves topical GHK-Cu formulations, not injectable ones. Extrapolating from skin cream studies to injection protocols is a logical leap the research does not support.
Fractionation as a concept is used in legitimate peptide research, but the specific claim that it produces "all the difference in results" needs evidence. Without knowing what results are being measured, how they are being tracked, and what comparator is being used, that statement is marketing language, not a clinical finding.
If you are considering GHK-Cu for any therapeutic purpose, the conversation belongs with a licensed clinician who can evaluate your specific situation, not a TikTok tutorial with an untranslatable audio track. Peptides can interact with existing conditions and medications in ways that are not always predictable, and reconstitution errors carry real infection risk.